A phase II study of spirogermanium in pa
✍
Elizabeth Eisenhauer; Ian Kerr; Audley Bodurtha; Neill Iscoe; Peter McCulloch; K
📂
Article
📅
1985
🏛
Springer US
🌐
English
⚖ 205 KB
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression oc